HK1244274A1 - C21h22ci2n4o2的晶型 - Google Patents

C21h22ci2n4o2的晶型

Info

Publication number
HK1244274A1
HK1244274A1 HK18103713.0A HK18103713A HK1244274A1 HK 1244274 A1 HK1244274 A1 HK 1244274A1 HK 18103713 A HK18103713 A HK 18103713A HK 1244274 A1 HK1244274 A1 HK 1244274A1
Authority
HK
Hong Kong
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
HK18103713.0A
Other languages
English (en)
Inventor
G‧德克雷斯森佐
D‧威爾施
P‧I‧弗拉霍瓦
S‧X‧M‧博爾裡格特
A‧阿羅諾夫
A‧凱沙瓦茲舒克裡
A‧N‧斯坎加斯
K‧絲塔芙羅伯洛斯
B‧利特勒
I‧N‧卡迪亞拉
R‧G‧阿拉高瓦
Original Assignee
生物醫學谷探索股份有限公司
沃泰克斯藥物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生物醫學谷探索股份有限公司, 沃泰克斯藥物股份有限公司 filed Critical 生物醫學谷探索股份有限公司
Publication of HK1244274A1 publication Critical patent/HK1244274A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK18103713.0A 2015-01-30 2018-03-16 C21h22ci2n4o2的晶型 HK1244274A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562110449P 2015-01-30 2015-01-30
PCT/US2016/015829 WO2016123574A1 (en) 2015-01-30 2016-01-29 Crystalline forms of c21h22ci2n4o2

Publications (1)

Publication Number Publication Date
HK1244274A1 true HK1244274A1 (zh) 2018-08-03

Family

ID=56544441

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103713.0A HK1244274A1 (zh) 2015-01-30 2018-03-16 C21h22ci2n4o2的晶型

Country Status (11)

Country Link
US (5) US9676746B2 (zh)
EP (1) EP3250562A4 (zh)
JP (4) JP7258460B2 (zh)
CN (2) CN116854662A (zh)
AU (4) AU2016211246B2 (zh)
CA (2) CA3218488A1 (zh)
HK (1) HK1244274A1 (zh)
MX (1) MX2017009696A (zh)
NZ (2) NZ772411A (zh)
SG (2) SG11201705924RA (zh)
WO (1) WO2016123574A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ772411A (en) 2015-01-30 2022-05-27 Vertex Pharma Crystalline forms of c21h22ci2n4o2
CA3008701A1 (en) * 2016-01-27 2017-08-03 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
US20230024584A1 (en) * 2019-11-20 2023-01-26 University Of Kentucky Research Foundation Anti-cancer compositions and methods
WO2023169480A1 (zh) * 2022-03-08 2023-09-14 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
TW202400572A (zh) * 2022-03-24 2024-01-01 美商生物醫學谷探索公司 Erk的吡咯抑制劑之氘化類似物、其合成及其中間物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
JP2545522B2 (ja) 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ，インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
JPH04506066A (ja) 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
ATE232540T1 (de) 1991-11-22 2003-02-15 Alcon Lab Inc Angiostatische steroide
SK14082001A3 (sk) 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003237121A1 (en) 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
ES2751761T3 (es) * 2004-05-14 2020-04-01 Vertex Pharma Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
ES2524021T3 (es) 2006-12-06 2014-12-03 Conatus Pharmaceuticals, Inc. Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
IN2015DN01662A (zh) * 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
NZ772411A (en) 2015-01-30 2022-05-27 Vertex Pharma Crystalline forms of c21h22ci2n4o2

Also Published As

Publication number Publication date
CN107406413A (zh) 2017-11-28
EP3250562A1 (en) 2017-12-06
JP7258460B2 (ja) 2023-04-17
US20190127348A1 (en) 2019-05-02
JP2023096080A (ja) 2023-07-06
SG10202101979TA (en) 2021-04-29
AU2020257041B2 (en) 2022-06-23
MX2017009696A (es) 2017-10-23
US10738027B2 (en) 2020-08-11
AU2020257041A1 (en) 2020-11-12
AU2016211246A1 (en) 2017-08-10
CA2975048C (en) 2024-01-02
AU2020257041C1 (en) 2022-10-27
US11390600B2 (en) 2022-07-19
JP2018503649A (ja) 2018-02-08
AU2016211246B2 (en) 2020-08-27
NZ772411A (en) 2022-05-27
CA3218488A1 (en) 2016-08-04
AU2023254937A1 (en) 2023-11-16
US20220324832A1 (en) 2022-10-13
US20170320851A1 (en) 2017-11-09
CN116854662A (zh) 2023-10-10
AU2022228084B2 (en) 2023-11-16
EP3250562A4 (en) 2018-07-11
AU2022228084A1 (en) 2022-09-29
US10183927B2 (en) 2019-01-22
SG11201705924RA (en) 2017-08-30
CA2975048A1 (en) 2016-08-04
JP2022033866A (ja) 2022-03-02
US20200339531A1 (en) 2020-10-29
WO2016123574A1 (en) 2016-08-04
NZ734041A (en) 2022-02-25
US9676746B2 (en) 2017-06-13
JP2020100674A (ja) 2020-07-02
US20160221987A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
HK1252845A1 (zh) 勞拉替尼游離碱的結晶形式
IL257026A (en) Solid state forms of eluxadoline
EP3136857A4 (en) Crystalline form of baricitinib
IL246385A0 (en) Crystalline forms of efitinib di-malate
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
HK1255112A1 (zh) 吉西他濱的晶型
HK1247125A1 (zh) 結晶化合物
ZA201706282B (en) Solid forms of menaquinols
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL253479A0 (en) Crystalline forms of efinconazole
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
IL265445A (en) crystalline forms
GB201419174D0 (en) Crystalline forms
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
IL269792B (en) Crystalline forms of (s)–apoxolner
HK1255148A1 (zh) 結晶形式
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
HUP1500506A2 (en) Salts of palbociclib
IL270937A (en) Crystalline forms of saltalicib
ZA201902553B (en) Crystalline forms